← Back to Clinical Trials
Recruiting NCT06684782

NCT06684782 Prevalence and Characteristics of Restless Leg Syndrome in Thai Patients With Parkinson's Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06684782
Status Recruiting
Phase
Sponsor Siriraj Hospital
Condition Restless Legs Syndrome
Study Type OBSERVATIONAL
Enrollment 310 participants
Start Date 2024-12-01
Primary Completion 2026-10-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type OBSERVATIONAL
Interventions
Screening for symptoms of restless leg syndrome

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 310 participants in total. It began in 2024-12-01 with a primary completion date of 2026-10-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by pathologic intraneuronal alpha-synuclein-positive Lewy bodies and neuronal cell loss. The cardinal clinical symptoms and signs of PD are bradykinesia, rigidity, tremor, postural instability, and freezing attacks. The prevalence of PD increases with age, affecting 1-2% of the population over the age of 65 years, and 3% of those over 85 years. Restless legs syndrome (RLS) represents disturbing symptoms in lower limbs that lead to the urge to move, occurring in rest periods. Movements can partially or completely relieve these abnormal feelings. In 2014, the International RLS Study Group (IRLSSG) established five mandatory criteria for the diagnosis of RLS. Several studies supported that RLS and PD may share pathophysiological mechanisms.

Eligibility Criteria

Inclusion Criteria: * Patients with Parkinson's disease aged from 18 to 80 years who met the United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank Diagnostic criteria. Exclusion Criteria: * Patients with atypical or secondary parkinsonism. * Patients with Mini-mental status exam (MMSE) less than 24 of 30. * Patients with secondary causes of restless leg syndrome including end-stage renal disease, iron deficiency anemia and pregnancy.

Contact & Investigator

Central Contact

Jindapa Srikajon, Doctor of Medicine

✉ jindapas@hotmail.com

📞 +66875932929

Principal Investigator

Jindapa Srikajon, Doctor of Medicine

PRINCIPAL INVESTIGATOR

Siriraj Sleep Center, Faculty of Medicine, Siriraj Hospital, Mahidol University

Frequently Asked Questions

Who can join the NCT06684782 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Restless Legs Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06684782 currently recruiting?

Yes, NCT06684782 is actively recruiting participants. Contact the research team at jindapas@hotmail.com for enrollment information.

Where is the NCT06684782 trial being conducted?

This trial is being conducted at Bangkok, Thailand, Bangkok, Thailand.

Who is sponsoring the NCT06684782 clinical trial?

NCT06684782 is sponsored by Siriraj Hospital. The principal investigator is Jindapa Srikajon, Doctor of Medicine at Siriraj Sleep Center, Faculty of Medicine, Siriraj Hospital, Mahidol University. The trial plans to enroll 310 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology